ERBB2 and breast cancer: Notably, the incidence of brain metastases in triple-negative breast cancer is 25–46%, and the time of brain metastasis is significantly earlier than that of HER2-positive breast cancer and hormone receptor-positive breast cancer (Jorns, Healy & Zhao, 2013).